Skip to main content

Table 1 Overview of aCGH findings in 46 prostate cancer samples

From: Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas

 

Frequency (n = 46)

SRO1

Size (Mb)

Genomic position (Mb)

Losses

    

8p

67.4%

8p21.2-8p22

12.0

15.36–27.36

5q

39.1%

5q13.1

5q13.2-5q13.3

5q21.1

5q22.2-5q23.1

0.6

2.1

2.0

7.7

66.79–67.41

71.74–73.87

99.03–101.09

112.07–119.75

16q

37.0%

16q12.1-16q12.2

16q22.2-16q22.3

16q23.3-16q24.1

4.1

1.7

3.6

49.70–53.86

70.70–72.37

81.20–84.83

6q

34.8%

6q14.1-6q14.3

6q16.2-6q22.31

3.5

23.6

82.59–86.12

99.38–123.02

10q

32.6%

10q23.31

10q26.3

1.0

2.6

89.69–90.69

130.01–132.63

13q

32.6%

13q14.1-13q14.3

13q21.32-13q21.33

5.5

4.7

39.49–45.03

66.42–71.16

17p

30.4%

17p13.1-17p13.2

2.3

6.14–8.49

12p

23.9%

12p13.2

1.9

10.93–12.86

Gains

    

8q

30.4%

8q11.21-8q12.1

8q13.2-8q24.23

10.8

68.2

48.76–59.73

68.36–136.56

7q

21.7%

7q11.21-7q11.22

7q21.11-7q22.1

6.3

19.5

64.63–71.01

80.26–99.76

  1. Aberrations occurring in less than 20% of the samples are not displayed.
  2. 1 Smallest region of overlap (often more than one per chromosomal arm).